How Povorcitinib May Expand Treatment Options for Challenging HS Populations

As phase 3 data for the investigational oral selective JAK1 inhibitor povorcitinib continue to emerge, Martina Porter, MD, of Beth Israel Deaconess Medical Center, believes the therapy has the potential to address important unmet needs for patients with hidradenitis suppurativa (HS), particularly those with refractory disease or those seeking alternatives to injectable biologics.

One of the most common treatment-emergent adverse events observed in the STOP-HS program was acne, occurring in just under 20% of participants. Porter noted that acne rates were similar between the 45-mg and 75-mg treatment groups through 54 weeks, despite early concerns that higher doses might increase risk. Importantly, nearly all cases were classified as mild, with only a small number considered moderate and no patients requiring treatment discontinuation because of severe acne.

Porter emphasized that interpreting acne incidence in HS trials requires clinical context. Acne and HS frequently coexist, and standard acne therapies, including oral antibiotics and isotretinoin, are typically prohibited during clinical trials because they could influence HS efficacy outcomes. As a result, investigators were unable to manage acne as aggressively as they would in routine practice. Based on her clinical experience using JAK inhibitors across multiple inflammatory diseases, Porter said acne associated with JAK inhibition is generally mild, follows a hormonal distribution, and can typically be managed using conventional acne treatment approaches once the medication becomes available in clinical practice.

“HS mostly affects younger females, and they're the ones who are much more likely to get hormonal acne. So to me, it wasn't really that surprising to see a lot more acne in this population,” she noted.

Beyond safety, Porter highlighted the potential role of povorcitinib in patients who have previously failed biologic therapy. Approximately one-third of trial participants had prior exposure to biologics, including TNF-α and IL-17 inhibitors. Although these patients entered the study with more severe disease and higher lesion counts, subgroup analyses presented at scientific meetings demonstrated treatment responses comparable to those seen in biologic-naïve patients.

According to Porter, these findings suggest that JAK1 inhibition may provide benefit through mechanisms distinct from currently approved biologic therapies. Because JAK1 signaling targets inflammatory pathways that differ from TNF-α and IL-17 inhibition, povorcitinib could become an important option for patients with inadequate responses to existing therapies and may eventually have a role in combination treatment strategies for the most refractory cases.

Porter also believes the availability of an oral therapy could improve treatment acceptance among younger patients who may be reluctant to initiate injectable medications. The shorter half-life of an oral agent may provide additional flexibility for patients compared with long-acting biologics.

Looking ahead, Porter envisions a more personalized approach to HS management as additional therapies become available. Based on her clinical experience, she has observed particularly favorable responses to JAK inhibition in 2 patient populations: individuals with severe, fistulizing disease resembling Crohn disease–associated HS and patients with longstanding nodular disease who have minimal tunneling, often with a strong family history. She also emphasized the importance of intervening earlier in the disease course before irreversible scarring and sinus tract formation occur, noting that future precision medicine approaches may help identify patients most likely to benefit during this potential "window of opportunity."

Missed Part 1 of the conversation? Catch up here.